Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2017

View Archived Issues

Lundbeck recaps progress of fourth quarter 2016

ASLAN Pharmaceuticals presents phase II results for varlitinib

Treatment with MD-1003 shows efficacy and safety in patients with progressive multiple sclerosis

Promising inhibitors of STOML3 oligomerization in treating tactile-driven pain following neuropathy

Kagoshima University identifies novel anti-hepatitis B virus agents

Neurocrine and Bial sign licensing agreement for opicapone in U.S. and Canada

SC-83288, a clinical development candidate with novel mode of action for the treatment of malaria

Update on phase III trials of NC-6004 for the treatment of pancreatic cancer

CEVEC Pharmaceuticals signs agreement with NewLink Genetics for use of its cell lines

Phase I results show UE-2343 is brain penetrant and well tolerated

Armetheon agrees with FDA on phase III study for oral anticoagulant

Tracon reports phase II topline results for TRC-105 in recurrent glioblastoma

Marathon Pharmaceuticals' Emflaza approved by FDA for DMD

Viking Therapeutics reports results on VK-2809 in model of GSD Ia

MRC, South African MRC and GSK partner to tackle noncommunicable diseases in Africa

MediWound reports favorable results from phase II study of NexoBrid

Ovid Therapeutics enters Angelman syndrome biomarker collaboration, begins phase II study

Tessa Therapeutics and A*STAR's IMCB collaborate on immuno-oncology lab

Copanlisib named FDA orphan drug for splenic, nodal and extranodal marginal zone lymphoma

FDA names laquinimod sodium an orphan drug for Huntington's disease

Generex continues process to acquire controlling equity interest in Emmaus Life Sciences

U.S. orphan drug designation granted to IMG-7289 for acute myeloid leukemia

Blood NF-L, a promising biomarker for differential diagnosis of parkinsonian disorder

Systems Oncology signs license agreement with University of Wisconsin-Milwaukee

Prevacus plans phase I studies of PRV-002 to treat concussion

Boehringer Ingelheim starts phase II trial to treat advanced squamous cell carcinoma of the lung

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...